HELLENIC SOCIETY OF CHEMOTHERAPY

IN COLLABORATION WITH
HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS

ATHENS **24-27** SEPTEMBER 2026

P R O G R A M M E

The daily concern for the critically ill:

EMBRACE the *FUTURE*

20th year anniversary of the Hellenic Sepsis Study Group

FREE ADMISSION

25 & 26 SEPTEMBER 2026, ACROPOLIS MUSEUM
27 SEPTEMBER 2026, AIGLI ZAPPEION

Pentaglobin®

Η ΖΩΗ. ΧΡΕΙΑΖΕΤΑΙ ΙΣΟΡΡΟΠΙΑ.

Παρασκεύασμα ανοσοσφαιρινών εμπλουτισμένο με IgM για την επικουρική θεραπεία σοβαρών βακτηριακών λοιμώξεων.

Biotest

From Nature for Life

SOME THOUGHTS FROM THE BOARD,

This annual conference of the Hellenic Society of Chemotherapy (HSC) coincides with the anniversary of 20 years since the start of the activities of the Hellenic Sepsis Study Group (HSSG). The big successes of the HSSG the last 20 years are neither the 146 publications in peer-reviewed journals nor the guidelines for sepsis management; the real achievement is how HSSG brought medical doctors and scientists of three different generations together and managed to generate strong bonds of coalition. The outcome of this coalition is obvious: pioneering in precision medicine to help the critically ill as this was done by the ImmunoSep trial and by the registration of anakinra for COVID-19.

Our Board can give only one promise: continue fighting for the scientific excellence of the medical generations to come,

Athens, September 2026

The Board of the Hellenic Society of Chemotherapy



BOARD OF DIRECTORS OF THE HELLENIC SOCIETY FOR CHEMOTHERAPY

Evangelos J. Giamarellos-Bourboulis, President
Symeon Metallidis, Vice President
Garyfallia Poulakou, General Secretary
Styliani Sympardi, Treasurer
Karolina Akinosoglou, Member
Ilias Karaiskos, Member
Evdoxia Kyriazopoulou, Member

HONORARY PRESIDENTS OF THE HELLENIC SOCIETY FOR CHEMOTHERAPY

Professor **Djillali Annane**
Professor **Helen Giamarellou**
Professor **Charalambos Gogos**
Professor **Georgios L. Daikos**
Professor **Kyriaki Kanellakopoulou**

WORKING GROUPS

HELLENIC SEPSIS STUDY GROUP :
Scientific Coordinators: **Ch. Gogos, E. J. Giamarellos-Bourboulis**

HELLENIC STUDY GROUP FOR PERSONALIZED INFECTION THERAPY
Scientific Coordinator: **S. Sympardi**

HELLENIC STUDY GROUP FOR COMBATING ANTIMICROBIAL RESISTANCE IN CRITICALLY ILL PATIENTS
Scientific Coordinator: **G. Poulakou, I. Karaiskos**

HELLENIC STUDY GROUP FOR COMBATING ANTIMICROBIAL RESISTANCE IN PATIENTS WITH SURGICAL INFECTIONS
Scientific Coordinator: **S. Metallidis**

HELLENIC STUDY GROUP FOR PUBLIC ENGAGEMENT IN COMBATING ANTIMICROBIAL RESISTANCE
Scientific Coordinators: **E. Giamarellou, K. Kanellakopoulou, G. Poulakou**

HELLENIC STUDY GROUP FOR THE STUDY OF INFECTIVE ENDOCARDITIS
Scientific Coordinator: **K. Akinosoglou**

HELLENIC STUDY GROUP FOR CAREER MENTORING OF YOUNG SCIENTISTS IN ANTIMICROBIAL THERAPY AND RESISTANCE
Scientific Coordinator: **E. Kyriazopoulou**

Those interested to become members of the HELLENIC SOCIETY FOR CHEMOTHERAPY and the Working Groups are kindly requested to contact Ms. Maltezaki at: **stamalt@med.uoa.gr**

PATHFAST

Sepsis Marker

Presepsin
B.R.A.H.M.S PCT

NT-proBNP
hs-cTnI
hsCRP
CK-MB mass
Myoglobin
D-Dimer

TB LAM Ag

Clinical need & challenges in infection healthcare
- Sepsis definition & clinical scores
- Diagnostic performance & clinical algorithm of Presepsin, PCT
- Diagnostic power & clinical algorithm of Presepsin & PCT together
- Marketing clinical use dual sepsis marker PCT & PSEP
- Marketing customer PCT & PSEP

PHC Europe B.V.

ΑΡΗΣΜΑΝΤΖΩΡΟΣ ΑΕ

15:00 - 19:00	**ON-GOING PROJECTS OF THE HELLENIC SEPSIS STUDY GROUP (Restricted attendance after invitation)**
	Study IMPRESS
	Study PROMISE
	Study CLASSIFY
	Study EXTENT
	Adjudicators: **M. Akova, D. Annane, A. Artigas**

Fomicyt®

fosfomycin i.v.

FOMICYT 2g / Vial (Bt x 10) N.T: € 138,51
FOMICYT 4g / Vial (Bt x 10) N.T: € 266,39

FOM/DPM/JAD/04_2025/01

Δυσίατες Ορθοπαιδικές Λοιμώξεις

*Συνδυαστική δράση σε πολυανθεκτικά Gram (+) & Gram (-) παθογόνα**

** ΠΧΠ Fomicyt*

Για την Περίληψη Χαρακτηριστικών Προϊόντος (ΠΧΠ) σαρώστε εδώ

Πριν τη συνταγογράφηση συμβουλευτείτε την ΠΧΠ, ή επικοινωνήστε με το τμήμα Επιστημονικής Ενημέρωσης της εταιρείας. Χορηγείται με περιορισμένη ιατρική συνταγή: Μόνο για νοσοκομειακή χρήση

Αναφέρετε κάθε εικαζόμενη / πιθανολογούμενη ανεπιθύμητη ενέργεια απευθείας στον ΕΟΦ, σύμφωνα με το εθνικό σύστημα αναφοράς ανεπιθύμητων ενεργειών.

ELPEN Α.Ε. Φαρμακευτική Βιομηχανία
Τμήμα Επιστημονικής Ενημέρωσης
Παπαδιαμαντοπούλου 41, 11528 Αθήνα, Τηλ: 2107756226
Εθνικής Αντιστάσεως 114, 55134 Θεσσαλονίκη, Τηλ: 2310459920-1
www.elpen.gr

ELPEN

flyingcolours

09:00 - 10:45	**EMBRACE THE CRITICALLY ILL**
	Chairperson: **P. Myrianthefs**
09:00 - 09:30	CLINICAL EVIDENCE
	A. Alevizou
09:30 - 10:00	TRANSLATIONAL RESULTS
	E. Stylianakis
10:00 - 10:30	PREDICT THE BEST CANDIDATE
	A. Kotsaki
10:30 - 10:45	DISCUSSION
10:45 - 13:30	**PROMISE and INSPIRE**
	Chairpersons: **G. Dimopoulos, D. Tsiftsis**
10:45 - 11:15	BIOMARKERS OF EARLY SEPSIS RECOGNITION
	D. Babales
11:15 - 11:40	HOW TO SELECT PATIENTS
	K. Leventogiannis
11:40 - 11:55	TECHNOLOGY ON OUR SIDE
	K. Dakou
11:55 - 12:10	STUDY MONITORING
	A. Kondyli
12:10 - 12:50	DISCUSSION WITH THE INVESTIGATORS OF THE PROMISE TRIAL (**S. Gerakari, E. Peitsidou, V. Koutsoukou**)
12:50 - 13:20	**BREAK**
13:20 - 16:15	**ADJUVANT THERAPIES FOR SEPSIS MANAGEMENT**
	Chairpersons: **M. Theodorakopoulou, P. Panagopoulos**
13:20 - 13:50	STEM CELL TRANSPLANTATION
	A. Artigas

13:50 - 14:25	CORTICOSTEROIDS AND BIOMARKERS: WHERE DO WE STAND?
	D. Annane
14:25 - 14:50	NEW ANTIBIOTICS AND ADJUVANT THERAPIES: IS THERE SOME COST BENEFIT?
	A. Markogiannakis
14:50 - 15:10	TREATING WITH INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS: PROS
	I. Kotsamidi
15:10 - 15:30	TREATING WITH INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS: CONS
	S. Antonopoulou
15:30 - 16:00	POSITIONING OF ADJUVANT THERAPIES IN THE BULLETIN OF SEPSIS: DISCUSSION BETWEEN PARTICIPANTS IN THE EDITORIAL GROUP
16:00 - 16:15	FINAL POSITIONING
	E. J. Giamarellos-Bourboulis
16:15 - 16:45	**SYNDROMIC TESTING AND FAST ANTIMICROBIAL SUSCEPTIBILITY TESTING: SPEEDING UP DIAGNOSIS AND THERAPY DECISION-MAKING FOR THE CRITICALLY ILL PATIENTS (SATELLITE SESSION)**
	Chairperson: **S. Metallidis** Speaker: **O. Tsachouridou**
16:45 - 18:00	**EARLY ANTIBIOTIC TREATMENT IS MAJOR PREREQUISITE: HOW TO DO IN ENVIRONMENTS OF MULTIDRUG-RESISTANCE?**
	Chairpersons: **C. Gogos, E. Mouloudi**
16:45 - 17:05	EPIDEMIOLOGY IN THE MEDITERRANEAN
	S. Pouriki
17:05 - 17:25	HOW TO DEAL WITH metallo-β-lactamases
	M. Akova



FRIDAY
25.09.2026

ACROPOLIS MUSEUM

17:25 - 17:45	CHOOSE TARGETED TREATMENT
	V. Petrakis
17:45 - 18:00	DISCUSSION
	This session aims to the vivid interaction of the speakers with the audience. Proceedings will be published.
18:00 - 19:00	**OPENING CEREMONY**
18:00 - 18:10	ADDRESS TO THE CONFERENCE
	Adonis Georgiadis, Minister of Health of Greece
18:10 - 18:20	ADDRESSES
	E. J. Giamarellos-Bourboulis, S. Metallidis
18:20 - 19:00	SEPSIS: A JOURNEY IN TIME
	Derek C. Angus
19:00 - 20:30	**GUIDED TOUR AT THE ACROPOLIS MUSEUM**



ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ: Κάθε φιαλίδιο περιέχει διφωσφορική οριταβανκίνη που ισοδυναμεί με 400 mg οριταβανκίνης. Μετά την ανασύσταση, 1 ml διαλύματος περιέχει 10 mg οριταβανκίνης. Μετά την αραίωση, 1 ml διαλύματος προς έγχυση περιέχει 1,2 mg οριταβανκίνης. Για τον πλήρη κατάλογο των εκδόχων, βλ. Π.Χ.Π. παράγραφο 6.1.

ΤΡΟΠΟΣ ΧΟΡΗΓΗΣΗΣ: Ενδοφλέβια έγχυση (εφάπαξ δόση) διάρκειας 3 ωρών.
ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ ΚΑΙ ΣΥΣΚΕΥΑΣΙΑ: PD.C.SO.IN 400MG/VIAL BT x 3 vials

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: Με Ιατρική συνταγή
Ν.Τ.: 1.991,68 €, **Λ.Τ.:** 2.418,50 €
Καλύπτεται από τα ασφαλιστικά ταμεία

Πριν τη συνταγογράφηση, παρακαλούμε συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος TENKASI® 400mg σκανάροντας το QR code.

TENKASI® 400mg SmPC (09/2023)

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Για περισσότερες πληροφορίες παρακαλούμε απευθυνθείτε στην εταιρεία Menarini Hellas

Menarini Hellas

Menarini Hellas A.E. - Πάτμου 16-18,
151 23, Μαρούσι, Αττική
Τ.: 210 8316111-13, F.: 210 8317343,
info@menarini.gr, www.menarini.gr

VABOREM®

meropenem/vaborbactam

ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:
Κάθε φιαλίδιο περιέχει τριυδρική μεροπενέμη ισοδύναμη με 1 g μεροπενέμης, και 1 g βαμπορβακτάμης. Μετά την ανασύσταση, 1 ml του διαλύματος περιέχει 50 mg μεροπενέμης, και 50 mg βαμπορβακτάμης.

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ: Χορηγείται με περιορισμένη ιατρική συνταγή, μόνο για νοσοκομειακή χρήση.

ΤΡΟΠΟΣ ΧΟΡΗΓΗΣΗΣ: Μέσω ενδοφλέβιας έγχυσης επί 3 ωρες.

Π.Χ.Π. VABOREM®: Ημερομηνία αναθεώρησης του κειμένου, 12/02/2026.

ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ	PD.C.S.INF (1+1)G/VIAL
ΝΟΣΟΚΟΜΕΙΑΚΗ ΤΙΜΗ	346,33€
ΛΙΑΝΙΚΗ ΤΙΜΗ	449,13€

Καλύπτεται από τα ασφαλιστικά ταμεία

Πριν την συνταγογράφηση, για πλήρεις συνταγογραφικές πληροφορίες και πληροφορίες σχετικά με την ασφάλεια και ανεκτικότητα παρακαλούμε συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος σκανάροντας το QR Code.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Για περισσότερες πληροφορίες και για την πλήρη Π.Χ.Π. παρακαλούμε απευθυνθείτε στην εταιρεία:

Menarini Hellas

Menarini Hellas A.E. - Πάτμου 16-18, 151 23
Μαρούσι, Αττική, Τ.: 210 8316111-13, F.: 210 8317343
info@menarini.gr, www.menarini.gr

GR-VAB-2-06-2026

SATURDAY
26.09.2026

ACROPOLIS MUSEUM

09:30 - 10:30	**CHALLENGING ROADMAPS FOR THE CRITICALLY ILL PATIENT**
	Chairperson: **M. Ntaganou**
09:30 - 09:50	INFECTION PREVENTION USING PROBIOTICS: MYTH OR REALITY
	S. Karakonstantis
09:50 - 10:20	THE ENTERIC NERVOUS SYSTEM: A NEUROINFLAM MATORY PARADIGM
	V. Pachnis
10:20 - 10:30	DISCUSSION
10:30 - 11:40	**TARGETED ANTIBIOTIC TREATMENT FOR THE CRITICALLY ILL (SATELLITE SESSION)**
	Chairperson: **Z. Mastora**
10:30 - 10:40	OPENING REMARKS
	Z. Mastora
10:40 - 11:05	INFECTIONS BY ESBL
	A. Kotsaki
11:05 - 11:30	INFECTIONS BY DIFFICULT-TO-TREAT PATHOGENS
	O. Tsachouridou
11:30 - 11:40	DISCUSSION

Colistin/Norma®

Colistimethate sodium

ΝΕΑ ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ



NORMA

Έδρα: Μενάνδρου 54, 10431 Αθήνα,
Τηλ.: 210 52.22.282, **Fax:** 210 52.41.368
E-mail: info@normahellas.gr
www.normahellas.gr

Υψηλή Ποιότητα Ελέγχου

ISO 9001 BUREAU VERITAS Certification

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

11:40 - 12:10	**IMMUNOMODULATION THROUGH ABSORBANCE OF INFLAMMATORY MEDIATORS (SATELLITE SESSION)**
	Chairperson: **D. Makris**
11:40 - 12:00	ABSORBING ENDOTOXINS AND THE EXTENT TRIAL
	G. Dimopoulos
12:00 - 12:10	DISCUSSION
12:10 - 13:40	**THE ROADMAP OF 2030**
	Chairpersons: **H. Giamarellou, K. Kanellakopoulou**
12:10 - 12:30	SEPSIS AS A GLOBAL PRIORITY
	G. A. Weiler
12:30 - 13:00	NOVEL CONSIDERATIONS IN THE DESIGN OF TRIALS FOR SEVERE INFECTIONS
	M. Cavaleri
13:00 - 13:40	DISCUSSION
13:40 - 14:30	**BREAK**
14:30 - 15:00	**COLISTIN: WHAT IS THE POSITIONING FOR 2030?**
	I. Karaiskos
15:00 - 16:00	**THERAPEUTIC CHALLENGES AND STRATEGIES IN THE MANAGEMENT OF SEVERE MULTIDRUG-RESISTANT INFECTIONS (SATELLITE SESSION)**
	Chairperson: **E. J. Giamarellos-Bourboulis**
15:00 - 15:25	PERSONALIZED APPROACH TO SEVERE GRAM (-) INFECTIONS
	E. Kyriazopoulou

15:25 - 15:50	PERSONALIZED APPROACH TO SEVERE GRAM (+) INFECTIONS
	A. Papadopoulos
15:50 - 16:00	DISCUSSION
16:00 - 18:15	**RAPID ANTIBIOTIC SUSCEPTIBILITY TESTING AND EMERGENCE OF RESISTANCE (IN COLLABORATION WITH THE HELLENIC MICROBIOLOGY SOCIETY)**
	Chairpersons: **G. Vrioni, G. Poulakou**
16:00 - 16:20	CURRENT PRACTICE FOR GRAM-NEGATIVE INFECTIONS INT THE ICU
	V. Soulountsi
16:20 - 16:40	RAPID AST: THE PRINCIPLES
	G. Vrioni
16:40 - 17:00	BEING FAST
	M. Orfanidou
17:00 - 17:20	MODIFY CLINICAL ACTIONS
	M. Adami
17:20 - 17:40	COMBINATION OF ANTIBIOTICS FOR CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII
	E. J. Giamarellos-Bourboulis
17:40 - 18:00	FUNGAL RESISTANCE: DOES THIS REALLY MATTER?
	A. Gkiouliava
18:00 - 18:15	DISCUSSION

Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
© 2026 Swedish Orphan Biovitrum AB (publ) – All rights reserved
Sobi: Σωρού 12, Μαρούσι 151 25, +30 210 700 81 00,
info.greece@sobi.com, www.sobi.com/greece/el
March 2026. NP-48619

sobi

11:00 - 12:00	**ANTIMICROBIAL STEWARDSHIP. WHERE DO WE STAND?**
	Chairperson: **A. Lavrentieva**
11:00 - 11:20	ANTIMICROBIAL STEWARDSHIP IN THE COMMUNITY
	V. Sakka
11:20 - 11:40	ANTIMICROBIAL STEWARDSHIP IN THE HOSPITAL ENVIRONMENT
	E. Bourgani
11:40 - 12:00	DISCUSSION
12:00 - 14:00	**2026 BULLETIN FOR SEPSIS AND SEPSIS CARE**
	Chairpersons: **E. J. Giamarellos - Bourboulis, S. Metallidis, G. Poulakou, A. Akinosoglou, I. Karaiskos**
	Speakers: Working group on new bulletin **Nikolaos Antonakos, Eleni Karakike, Evdoxia Kyriazopoulou**
14:00 - 14:30	BREAK

14:30 - 16:30	**WORKING GROUP CONTRIBUTIONS BY THE HELLENIC SOCIETY OF CHEMOTHERAPY**
	Chairperson: **S. Metallidis**
14:30 - 14:50	SURGICAL INFECTIONS
	T. Mihailidis
14:50 - 15:10	HEART of innovation
	K. Akinosoglou
15:10 - 15:30	HOW THE INFECTIOUS DISEASE EXPERTS CONSIDER PRECISION TREATMENT
	S. Sympardi
15:30 - 15:50	REGISTRY OF NEW ANTIBIOTICS
	G. Poulakou
15:50 - 16:10	HOW TO BOOST CAREER OF THE YOUNGER?
	P. Kazakou
16:10 - 16:30	DISCUSSION

Lacto Levure®

Νο1 προβιοτικό στην Ελλάδα*
* ΚΟΙΛΑ ΝΕΛΛΑΣ
DTC MARKET 01/2025

Νέα προοπτική

Συμπλήρωμα διατροφής για την **προστασία**
& την **αποκατάσταση** της **εντερικής χλωρίδας**

✓ **4** προβιοτικά - **5,5 δισ.** ζωντανά κύτταρα

- Saccharomyces boulardii
- Bifidobacterium lactis
- Lactobacillus acidophilus
- Lactobacillus plantarum

• **Αρ. Γνωστ. ΕΟΦ: 89375/16-12-2011** *(Το προϊόν δεν υπόκειται σε διαδικασία αδειοδότησης).*
Τα συμπληρώματα διατροφής δεν υποκαθιστούν τη συνήθη δίαιτα. Να φυλάσσεται μακριά από παιδιά.

ΒΡΑΒΕΥΜΕΝΟ

PRIX GALIEN GREECE 2025 ATHENS
BEST NUTRACEUTICAL PRODUCT

UNI-PHARMA
Pharmaceutical Laboratories S.A.

top EMPLOYER Ελλάδα Greece 2026
FOR A BETTER WORLD OF WORK
ΓΙΑ 4η ΣΥΝΕΧΟΜΕΝΗ ΧΡΟΝΙΑ

62 ΧΡΟΝΙΑ
62 χρόνια UNI-PHARMA.
Αξία για τον άνθρωπο.
Ευθύνη για την κοινωνία.

14ο χλμ. Εθνικής Οδού 1, 145 64 Κηφισιά
Τηλ.: 210-80 72 512, Fax: 210-80 78 907
e-mail: unipharma@uni-pharma.gr
www.uni-pharma.gr

LIST OF SPEAKERS AND CHAIRPERSONS

Dr. Marco Cavaleri, European Medicines Agency Head of Office, Biological Health Threats and Vaccines Strategy Head of Emergency Task Force Amsterdam, Netherlands

Professor Murat Akova, Professor of Medicine and the Chief of the Department of Infectious Diseases and Clinical Microbiology at Hacettepe University School of Medicine in Türkiye

Derek C. Angus Chair, Department of Critical Care Medicine, UPMC and the University of Pittsburgh Distinguished Professor and the Mitchell P Fink Endowed Chair Associate Vice Chancellor for Healthcare Innovation University of Pittsburgh Schools of the Health Sciences Senior editor, JAMA

Professor Djillali Annane, Professor at University Versailles - University Paris Saclay, Director of General ICU at Raymond Poincaré Hospital, Director of IHU PROMETHEUS, Honorary Dean of Medical School Simone Veil, Chairman of the Health Ministry Task Force against Sepsis, member of the board of governors of the American Hospital of Paris, President of the French Society of Intensive Care Medicine, Honorary President of the Hellenic Society for Chemotherapy

Professor Antonio Artigas Raventós, Applied Physiology. Autonomous University of Barcelona, Emeritus Director, Critical Care Centre, Parc Tauli University Hospital, Spain, Director, Sepsis and Acute Respiratory Failure Research Program, Honorary Member and Medal of Honour Recipient European Society of Intensive Care Medicine (ESIC)

Vassilis Pachnis Group Leader in the Development and Homeostasis of the Nervous System Laboratory at the Francis Crick Institute

Dr Gundo Aurel Weiler Head of Mission and Representative of the World Health Organization to Greece

Maria Evangelia Adami, Consultant in Internal Medicine, 1st Department of Internal Medicine, General Hospital of Athens "G. Gennimatas"

Karolina Akinosoglou, Professor of Internal Medicine, Department of Internal Medicine, School of Medicine, University of Patras, Executive Board Member of the Hellenic Society for Chemotherapy

Antonia Alevizou, MD, 4th Department of Internal Medicine. School of Medicine, National and Kapodistrian University of Athens

Nikolaos Antonakos Adjunct Lecturer of Internal Medicine and Infectious Diseases, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens

Sofia Antonopoulou Consultant, Intensive Care Unit, General Hospital of Athens "G. Gennimatas"

Dimitrios Babales Head Emergency Department, Larissa General Hospital "Koutlibaneion and Triantafylleion"

Eirini Bourgani Consultant, New Intensive Care Unit, General Hospital for Thoracic Diseases of Athens "Sotiria"

Konstantina Dakou Clinical Database Architect and eCRF website Administrator, Head of Computational Department of the Hellenic Institute for the Study of Sepsis

George Dimopoulos Professor of Pulmonary and Critical Care Medicine, Director of the ICU, Head of the 3rd Department of Critical Care Medicine

Helena Florou Clinical Pharmacist, MPharm, MSc, Medical Project Manager, Hellenic Institute for the Study of Sepsis

Styliani Gerakari, Head Emergency Department, General Hospital of Piraeus "Tzaneion"

Evangelos J. Giamarellos-Bourboulis Professor of Internal Medicine-Infectious Diseases, Director of the MSc Program "Infectious Diseases," 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, President of the Hellenic Institute for the Study of Sepsis, Chairman, European Sepsis Alliance; Board Member, Global Sepsis Alliance, President of the Hellenic Society for Chemotherapy

Helen Giamarellou, MD, PhD, FIDSA Em. Professor of Internal Medine Athens University Medical School - Infectious Diseases Specialist Head, 1st Departmemt of Internal Medicine-Infectious Diseases, Hygeia General Hospital Member of Academia Europaea, Honorary President of the Hellenic Society of Chemotherapy

Anna Gkiouliava Assistant Professor of Anesthesiology, Aristotle University of Thessaloniki, Anesthesiology and Intensive Care Unit, AHEPA University General Hospital of Thessaloniki

Charalambos Gogos Professor of Medicine at Patras University School of Medicine and Chairman of the Department of Medicine and Director of the Infectious Diseases Unit in Patras University Hospital, Director of the Internal Medicine and Infectious Diseases Department at Metropolitan General Hospital, Coordinator of the Hellenic Sepsis Study Group, President of the Hellenic Society for the Study and Management of AIDS, Honorary President of the Hellenic Society for Chemotherapy

Kyriaki Kanellakopoulou Professor of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens; Secretary of the Hellenic Institute for the Study of Sepsis; Honorary President of the Hellenic Society for Chemotherapy

Ilias Karaiskos Consultant, Department of Infectious Diseases, "Hygeia" Hospital; Executive Board Member of the Hellenic Society for Chemotherapy

Eleni Karakike Assistant Professor of Critical Care Medicine, School of Nursing, National and Kapodistrian University of Athens; Intensive Care Unit, General Oncology Hospital of Kifissia "Agioi Anargyroi"

Stamatis Karakonstantis Assistant Professor of Internal Medicine, School of Medicine, University of Crete, Department of Internal Medicine, University Hospital of Heraklion

Pinelopi Kazakou Consultant in Infectious Diseases, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens

Afroditi Kondyli MPharm, MSc, Head CRA of the Hellenic Institute for the Study of Sepsis

Antigoni Kotsaki Assistant Professor of Internal Medicine and Infectious Diseases, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Chief Scientific Officer of the Hellenic Institute for the Study of Sepsis, Councelor for the European Shock Society

Ioanna Kotsamidi Consultant, Intensive Care Unit, Hippokration General Hospital of Thessaloniki

Victoria Koutsoukou Director of Anesthesiology and Emergency Medicine Physician, General Hospital of Athens “G. Gennimatas”

Evdoxia Kyriazopoulou, Assistant Professor of Critical Care Medicine, School of Nursing, National and Kapodistrian University of Athens; Intensive Care Unit, General Oncology Hospital of Kifissia “Agioi Anargyroi”

Athina Lavrentieva Chairman, 1st Intensive Care Unit (ICU) “G. Papanikolaou” General Hospital

Konstantinos Leventogiannis Adjunct Lecturer of Internal Medicine and Infectious Diseases, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Chief Medical Officer of the Hellenic Institute for the Study of Sepsis

Dimosthenis Makris Professor of Intensive Care Medicine, Director of the Intensive Care Unit, Larissa University General Hospital

Antonios Markogiannakis Director of Pharmacy, General Hospital of Athens “Laiko”

Zafeiria Mastora Director of the Intensive Care Unit, General Hospital for Thoracic Diseases of Athens “Sotiria”, President of the Hellenic Society of Intensive Care Medicine

Symeon Metallidis Professor of Internal Medicine - Infectious Diseases; Director, 1st Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki; Vice President of the Hellenic Society for Chemotherapy

Theodore Mihailidis, Consultant in Internal Medicine, 1st Department of Internal Medicine, Aristotle University of Thessaloniki

Eleni Mouloudi Director of the Intensive Care Unit, Hippokration General Hospital of Thessaloniki

Pavlos Myrianthefs Professor of Critical Care and Pulmonary Medicine, National and Kapodistrian University of Athens; General Oncology Hospital of Kifissia “Agioi Anargyrol”

Maria Ntaganou Director of the Intensive Care Unit, General Hospital for Thoracic Diseases of Athens “Sotiria”

Maria Orfanidou Director of the Microbiology Laboratory, General Hospital of Athens “G. Gennimatas”

Periklis Panagopoulos Professor of Internal Medicine, 2nd University Department of Internal Medicine-University General Hospital Alexandroupolis

Antonios Papadopoulos Professor of Internal Medicine-Infectious Diseases, 4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens

Eleni Peitsidou MD, PhD General Practioner, Emergency Doctor Director of Emergency Department G.Papanikolaou Hospital, Vice-President of Hesem

Vasileios Petrakis Assistant Professor of Internal Medicine, 2nd University Department of Internal Medicine-University General Hospital Alexandroupolis

Garyfallia Poulakou Associate Professor of Internal Medicine-Infectious Diseases, 3rd Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens; General Secretary of the Hellenic Society for Chemotherapy

Sofia Pouriki Consultant, Intensive Care Unit, General Hospital for Thoracic Diseases of Athens "Sotiria"

Vissaria Sakka Consultant, 3rd University Department of Internal Medicine, General Hospital for Thoracic Diseases of Athens "Sotiria"

Vasiliki Soulountsi Consultant in Internal Medicine and Intensive Care Medicine, Director, 1st Intensive Care Unit (ICU) "G. Papanikolaou" General Hospital

Emmanouil Stylianakis Molecular Biologist and Geneticist, Bioinformatician, Hellenic Institute for the Study of Sepsis

Styliani Sympardi Infectious Diseases Specialist; Director, 1st Department of Internal Medicine, "Thriasio" Elefsina General Hospital, Treasurer of the Hellenic Society for Chemotherapy

Maria Theodorakopoulou Director of the Intensive Care Unit I, KAT General Hospital of Attica, President of the European Society of Intensive Care Medicine

Olga Tsachouridou Assistant Professor, 1st Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki

Dimitrios Tsiftsis Head Emergency Department, General Hospital of Nikaia "Aghios Paneteleimon"

Georgia Vrioni Professor of Microbiology, School of Medicine, National and Kapodistrian University of Athens

SATELLITE SESSIONS

FRIDAY **25.09.2026**

16:15 - 16:45	**SYNDROMIC TESTING AND FAST ANTIMICROBIAL SUSCEPTIBILITY TESTING: SPEEDING UP DIAGNOSIS AND THERAPY DECISION-MAKING FOR CRITICALLY ILL PATIENTS**
	Chairperson: **S. Metallidis**
	Speaker: **O. Tsachouridou**

SATURDAY **26.09.2026**

10:30 - 11:40	**TARGETED ANTIBIOTIC TREATMENT FOR THE CRITICALLY ILL**
	Chairperson: **Z. Mastora**
10:30 - 10:40	**OPENING REMARKS**
	Z. Mastora
10:40 - 11:05	**INFECTIONS CAUSED BY ESBL-PRODUCING PATHOGENS**
	A. Kotsaki

SATELLITE SESSIONS

11:05 - 11:30	**INFECTIONS CAUSED BY DIFFICULT-TO-TREAT PATHOGENS**
	O. Tsachouridou
11:30 - 11:40	DISCUSSION
11:40 - 12:10	**IMMUNOMODULATION THROUGH THE ABSORPTION OF INFLAMMATORY MEDIATORS**
	Chairperson: **D. Makris**
11:40 - 12:00	**ABSORBING ENDOTOXINS AND THE EXTENT TRIAL**
	G. Dimopoulos
12:00 - 12:10	DISCUSSION
15:00 - 16:00	**THERAPEUTIC CHALLENGES AND STRATEGIES IN THE MANAGEMENT OF SEVERE MULTIDRUG-RESISTANT INFECTIONS**
	Chairperson: **E. J. Giamarellos-Bourboulis**
15:00 - 15:25	**PERSONALIZED APPROACH TO SEVERE GRAM-NEGATIVE INFECTIONS**
	E. Kyriazopoulou
15:25 - 15:50	**PERSONALIZED APPROACH TO SEVERE GRAM-POSITIVE INFECTIONS**
	A. Papadopoulos
15:50 - 16:00	DISCUSSION

CONGRESS INFORMATION

CONGRESS VENUE ON **25 & 26** SEPTEMBER 2026:

ACROPOLIS MUSEUM
Dionysiou Areopagitou 15
117 42 Athens // Phone :+30 210 9000900

CONGRESS VENUE ON **27** SEPTEMBER 2026:

AIGLI
Zappeion Garden 15
105 57 Athens // Phone :+30 214 4099800

REGISTRATION :

Registration is **free of charge** and can be made only through congress website :
https://imaginecongress.gr/critical-care-congress-athens/

LANGUAGE :

Greek and English

CERTIFICATE OF ATTENDANCE :

Certificates of attendance will be issued electronically after the conference has concluded and once the online evaluation form has been completed

CME :

The Conference offers 22,5 CME credits

CONGRESS ORGANIZERS :

Imagine Congress and Travel
9, Kolokotroni street - 105 62 Athens -Greece
Phone: +30 210 3252520,
E mail : v.antonopoulou@imaginecongress,gr

WE SINCERELY THANK OUR SPONSORS FOR THEIR VALUABLE SUPPORT IN ORGANIZING THE CONFERENCE

ARIS MANTZOROS

BIOMERIEUX

ELPEN

MENARINI HELLAS

MSD

NORMA

PRISUM

SOBI

SYNEOS Health

UNI-PHARMA

VERMA DRUGS

Colistin/Norma®

Colistimethate sodium



NORMA

Έδρα: Μενάνδρου 54, 10431 Αθήνα,
Τηλ.: 210 52.22.282, **Fax:** 210 52.41.368
E-mail: info@normahellas.gr
www.normahellas.gr

Υψηλή Ποιότητα Ελέγχου

ISO 9001 BUREAU VERITAS Certification

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

MSD

Τοπικός Αντιπρόσωπος:
MSD Α.Φ.Ε.Ε.
Αγίου Δημητρίου 63, 17456 Άλιμος
Αρ. ΓΕΜΗ 121808101000
Τηλ: +30 210 98 97 300
dpoc.greece@msd.com

Συμβουλευτείτε τις Περιλήψεις Χαρακτηριστικών Προϊόντων πριν τη συνταγογράφηση.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε:
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Για την ΠΧΠ ZERBAXA σκανάρετε εδώ

ZERBAXA PD.C.SO.IN (1+0.5)G/VIAL
BTx10 VIALS: N.T.: 722,96€, Λ.Τ. : 903,46€

Για την ΠΧΠ RECARBRIO σκανάρετε εδώ

RECARBRIO PD.SOL.INF (500+500+250)MG/VIAL
BTx25 VIALS: N.T. 3.248,66€, Λ.Τ. 3.906,57€

GR-TIX-00087-30/01/2024-V6